Showing results (1901-1910 of 8,157) with videos related to
Sort By:
Pageof 816
Haematologica|June 15, 2023
Characterization of genetic variants in the EGLN1/PHD2 gene identified in a European collection of patients with erythrocytosisMarine Delamare, Amandine Le Roy, Mathilde Pacault, et al.Haematologica|June 15, 2023
Salvage radiotherapy in relapsed/refractory large B-cell lymphoma after failure of CAR T-cell therapyHazim S Ababneh, Andrea K Ng, Matthew J Frigault, et al.Haematologica|March 12, 2026
The expanding spectrum of CAR-T related T-cell lymphomasTheresa Schönrade, Till BraunHaematologica|March 12, 2026
Circulating T follicular helper cells as emerging biomarkers in pediatric Evans syndromeTaylor Olmsted Kim, John W SempleHaematologica|March 12, 2026
Management of chronic myeloid leukemia with tyrosine kinase inhibitors: adverse events, toxicities and therapy dosingVivian G Oehler, Ellin Berman, Ivan J HuangHaematologica|March 12, 2026
NSUN2-FOSB reciprocity facilitates leukemogenesis in an m5C-dependent manner by increasing BCL2L1 expressionBin Zhou, Yigang Yuan, Yue Cai, et al.Haematologica|February 19, 2026
Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudilFrancesca Bonifazi, Marcello Roberto, Maria Teresa Lupo Stanghellini, et al.Haematologica|February 26, 2026
Anti-programmed cell death protein 1-based salvage therapy for relapsed/refractory Hodgkin lymphoma: a multicenter real-world analysisHishan Tharmaseelan, Lisa M Sgonina, Ina Bühnen, et al.Haematologica|February 26, 2026
The dilemma after chimeric antigen receptor T-cell therapy - to transplant or not?Elad Jacoby, Bella BieloraiHaematologica|February 26, 2026
Comment on: Severe toxicity and poor efficacy of reinduction chemotherapy are associated with overall poor outcomes in relapsed B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group AALL1331 trialAibibai Mohetaer, Jianping HaoPageof 816